The association between antithrombotics (ATs) and the risk of gastrointestinal bleeding is well known; however, data regarding the influence of ATs on outcomes are scarce. The goals of this study are: (i) to assess the impact of prior AT therapy on in-hospital and 6-month outcomes and (ii) to determine the re-initiation rate of the ATs after a bleeding event. All patients with upper gastrointestinal bleeding (UGB) who underwent urgent gastroscopy in three centres from 1 January 2019 to 31 December 2019 were retrospectively analysed. Propensity score matching (PSM) was used. Among 333 patients [60% males, mean age 69.2 (±17.3) years], 44% were receiving ATs. In multivariate logistic regression, no association between AT treatment and worse in-hospital outcomes was observed. Development of haemorrhagic shock led to worse survival [odds ratio (OR) 4.4, 95% confidence interval (CI) 1.9-10.2, P < 0.001; after PSM: OR 5.3, 95% CI 1.8-15.7, P = 0.003]. During 6-months follow-up, higher age (OR 1.0, 95% CI 1.0-1.1, P = 0.002), higher comorbidity (OR 1.4, 95% CI 1.2-1.7, P < 0.001), a history of cancer (OR 3.6, 95% CI 1.6-8.1, P < 0.001) and a history of liver cirrhosis (OR 2.2, 95% CI 1.0-4.4, P = 0.029) were associated with higher mortality. After a bleeding episode, ATs were adequately re-initiated in 73.8%. Previous AT therapy does not worsen in-hospital outcomes in after UGB. Development of haemorrhagic shock predicted poor prognosis. Higher 6-month mortality was observed in older patients, patients with more comorbidities, with liver cirrhosis and cancer.
- Publikační typ
- časopisecké články MeSH
AIM: To evaluate the frequency of the loss of the Adenomatous Polyposis Coli (APC) protein and to compare the APC status with the characteristics of colorectal adenomas. METHODS: Immunohistochemical analysis of the APC protein was performed on 118 adenomas and the results were compared with parameters of malignant potential, location of adenomas, macroscopic appearance and age of the patients. RESULTS: A complete loss of the APC protein was found in 28 (24%) adenomas, while 90 (76%) were APC positive. The mean size of adenomas was 13.5 +/- 14.2 mm (95% CI 10.5-16.5) in APC-positive, and 13.8 +/- 15.5 mm (95% CI 7.8-19.8) in APC-negative adenomas (P = 0.364). Statistical analysis revealed no difference between APC-positive and negative adenomas as to the histological type (P = 0.327) and grade of dysplasia (P = 0.494). We found that even advanced adenomas did not differ in their APC status from the non-advanced tumors (P = 0.414). Finally, no difference was found when the location (P = 0.157), macroscopic appearance (P = 0.571) and age of patients (P = 0.438) were analysed and compared between both APC positive and negative adenomas. CONCLUSION: Most adenomas expressed full-length APC protein, suggesting that protein expression is not a reliable marker for assessment of APC gene mutation. Complete loss of APC protein did not influence morphology, location, or appearance of adenomas, nor was it affected by the patient's age.
- MeSH
- adenom genetika chemie patologie MeSH
- dospělí MeSH
- fenotyp MeSH
- financování organizované MeSH
- imunohistochemie MeSH
- kolorektální nádory genetika chemie patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- mutační analýza DNA MeSH
- nádorové biomarkery analýza MeSH
- protein familiární adenomatózní polypózy analýza genetika MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stanovení celkové genové exprese MeSH
- stupeň závažnosti nemoci MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
Účel studie: Crohnova nemoc je onemocnění doprovázené malabsorpcí žlučových kyselin. Pacienti s touto chorobou mají současně vyšší riziko vzniku pigmentové cholelitiázy. Cílem předkládané práce bylo zhodnotit přínos stanovení sérových koncentrací 7α-hydroxy-4-cholesten-3-onu (cholestenu), nového markeru malabsorpce žlučových kyselin, pro predikci rizika vzniku cholelitiázy u pacientů s Crohnovou nemocí. Metody: Sérové koncentrace cholestenu byly stanoveny pomocí vysokoúčinné kapalinové chromatografie u 84 pacientů s Crohnovou nemocí (z toho 17 mělo cholecystolitiázu či biliární sludge), 16 pacientů s ulcerózní kolitidou a 49 zdravých kontrol. Výsledky: Koncentrace cholestenu v séru ve skupině pacientů s Crohnovou nemocí s cholecystopatií byly výrazně vyšší než u jedinců bez cholecystopatie (medián [25-75 %]): 180,1 [51-320] vs 40,2 µg/l [14-103]; p < 0,00001. Závěry: Koncentrace cholestenu v séru se jeví důležitým prediktorem rizika vzniku cholecystolitiázy a měly by být rutinně vyšetřovány u všech pacientů s Crohnovou nemocí.
Aim of the study: Crohn's disease is commonly accompanied with bile salt malabsorption. Simultaneously, affected subjects have higher risk of pigment gallstone formation. The aim of presented study was to assess the role of serum 7α-hydroxy-4-cholesten-3-on (cholesten), a novel marker of bile salt malabsorption, for prediction of risk of gallstone disease in patients with Crohn's disease. Methods: Serum levels of cholesten were determined by HPLC in 84 patients with Crohn's disease (17 with cholecystolithiasis or biliary sludge), 16 patients with ulcerative colitis and 49 healthy control subjects. Results: Serum cholesten levels were found to be substantially elevated in patients with Crohn's disease and cholecystopathy as compared to those without biliary problems (median (25-75%): 180.1 (51-320) vs 40.2 µg/L (14-103), p < 0.00001. Conclusions: Serum cholesten levels seem to be an important predictor of gallstone disease and should be routinely examined in all patients with Crohn's disease.
- MeSH
- cholelitiáza diagnóza epidemiologie etiologie MeSH
- cholesteny krev MeSH
- Crohnova nemoc komplikace metabolismus MeSH
- finanční podpora výzkumu jako téma MeSH
- hodnocení rizik MeSH
- lidé MeSH
- malabsorpční syndromy diagnóza MeSH
- močové kameny diagnóza epidemiologie etiologie MeSH
- žlučové kyseliny a soli metabolismus MeSH
- Check Tag
- lidé MeSH
